{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:04Z","timestamp":1793018104437,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01886-9","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:23:29Z","timestamp":1790925809000},"page":"5619-5633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baricitinib Efficacy Through 4 Years in Responders and Safety up to 5 Years in Adults with Severe Alopecia Areata: Final Results from BRAVE-AA1 and BRAVE-AA2"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct03570749","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03899259","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ruth Ann","family":"Vleugels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Mesinkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Sontag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionn","family":"McSwiney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najwa","family":"Somani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitendra","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Denning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"1886_CR1","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, et al. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"1886_CR2","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaad.2019.05.086","volume":"88","author":"JP Okhovat","year":"2023","unstructured":"Okhovat JP, et al. Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2023;88(5):1040\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1886_CR3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","volume":"11","author":"A Mostaghimi","year":"2021","unstructured":"Mostaghimi A, et al. Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review. Dermatol Ther (Heidelb). 2021;11(3):867\u201383.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1886_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","volume":"79","author":"LY Liu","year":"2018","unstructured":"Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79(3):556-558.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1886_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","volume":"4","author":"NVJ Aldhouse","year":"2020","unstructured":"Aldhouse NVJ, et al. \u201c\u2018You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed:\u201d a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020;4(1):76.","journal-title":"J Patient Rep Outcomes"},{"issue":"10","key":"1886_CR6","doi-asserted-by":"publisher","first-page":"967","DOI":"10.36849\/JDD.SF396143","volume":"22","author":"A Tosti","year":"2023","unstructured":"Tosti A. Alopecia areata: the clinician and patient voice. J Drugs Dermatol. 2023;22(10):967\u201375.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1886_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","volume":"55","author":"A Tosti","year":"2006","unstructured":"Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55(3):438\u201341.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1886_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/1744666X.2023.2200166","volume":"19","author":"CM Kincaid","year":"2023","unstructured":"Kincaid CM, Arnold JD, Mesinkovska NA. Baricitinib as the first systemic treatment for severe alopecia areata. Expert Rev Clin Immunol. 2023;19(6):565\u201373.","journal-title":"Expert Rev Clin Immunol"},{"issue":"18","key":"1886_CR9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"3","key":"1886_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon O, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443\u201351.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1886_CR11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jdv.16948","volume":"35","author":"T Bieber","year":"2021","unstructured":"Bieber T, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1886_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81(3):335\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1886_CR13","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","volume":"39","author":"T Bieber","year":"2022","unstructured":"Bieber T, et al. A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv Ther. 2022;39(11):4910\u201360.","journal-title":"Adv Ther"},{"key":"1886_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25644","author":"AV Ramanan","year":"2025","unstructured":"Ramanan AV, et al. Effectiveness and safety of baricitinib for juvenile idiopathic arthritis associated uveitis or chronic anterior antinuclear antibody positive uveitis. Arthritis Care Res (Hoboken). 2025. https:\/\/doi.org\/10.1002\/acr.25644.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"1886_CR15","doi-asserted-by":"publisher","first-page":"2411834","DOI":"10.1080\/09546634.2024.2411834","volume":"35","author":"A Wollenberg","year":"2024","unstructured":"Wollenberg A, et al. Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years. J Dermatolog Treat. 2024;35(1):2411834.","journal-title":"J Dermatolog Treat"},{"key":"1886_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00932-0","author":"B King","year":"2025","unstructured":"King B, et al. Safety of baricitinib in adults with severe alopecia areata from two phase III trials over a median of 2.3 years and up to 4 years of treatment. Am J Clin Dermatol. 2025. https:\/\/doi.org\/10.1007\/s40257-025-00932-0.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1886_CR17","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40257-020-00545-9","volume":"21","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, et al. Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata. Am J Clin Dermatol. 2020;21(5):725\u201332.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1886_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/bjd.19024","volume":"183","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, et al. Development of the Scalp Hair Assessment PRO\u2122 measure for alopecia areata. Br J Dermatol. 2020;183(6):1065\u201372.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1886_CR19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jamadermatol.2024.2734","volume":"160","author":"B King","year":"2024","unstructured":"King B, et al. Baricitinib withdrawal and retreatment in patients with severe alopecia areata: the BRAVE-AA1 randomized clinical trial. JAMA Dermatol. 2024;160(10):1075\u201381.","journal-title":"JAMA Dermatol."},{"issue":"11","key":"1886_CR20","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1080\/1744666X.2023.2249237","volume":"19","author":"K Tokareva","year":"2023","unstructured":"Tokareva K, et al. JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023;19(11):1385\u201397.","journal-title":"Expert Rev Clin Immunol"},{"key":"1886_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00323-4","author":"J Thorley","year":"2021","unstructured":"Thorley J. FDA expands JAK inhibitors warning: going beyond the data? Lancet Rheumatol. 2021. https:\/\/doi.org\/10.1016\/S2665-9913(21)00323-4.","journal-title":"Lancet Rheumatol"},{"key":"1886_CR22","unstructured":"King B, et al Duration of current episode of alopecia Areata (AA) influences prognosis during treatment with baricitinib in patients with severe AA. In: World Congress of Dermatology-25th. 2023. Singapore."},{"key":"1886_CR23","doi-asserted-by":"crossref","unstructured":"King, B., et al. Impact of disease history on the efficacy of ritlecitinib (PF-06651600) in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b\/3 Study. In: European Academy of Dermatology and Venereology Congress. 2022. Milan, Italy.","DOI":"10.25251\/skin.6.supp.101"},{"key":"1886_CR24","unstructured":"European Medicines Agency. Olumiant: summary of product characteristics. EMA. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant. Accessed 21 May 2026."},{"issue":"3","key":"1886_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/jdv.19665","volume":"38","author":"M Senna","year":"2024","unstructured":"Senna M, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024;38(3):583\u201393.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1886_CR26","first-page":"490","volume":"39","author":"A Mostaghimi","year":"2024","unstructured":"Mostaghimi A, et al. Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow\/eyelash regrowth in the first year. J Eur Acad Dermatol Venereol. 2024;39:490\u20132.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"9","key":"1886_CR27","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamadermatol.2023.2581","volume":"159","author":"JM Ko","year":"2023","unstructured":"Ko JM, et al. Clinical outcomes for uptitration of baricitinib therapy in patients with severe alopecia areata: a pooled analysis of the BRAVE-AA1 and BRAVE-AA2 trials. JAMA Dermatol. 2023;159(9):970\u20136.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01886-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01886-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01886-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:03:39Z","timestamp":1793016219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01886-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1886"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01886-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ruth Ann Vleugels is a paid consultant for ArgenX, Abbvie, Astra Zeneca, Priovant, and Lilly. Bianca Maria Piraccini has served as a consultant for Pierre fabre-Ducray, Difa Cooper, Dercos-L\u2019Oreal, ISDIN, Legacy Healthcare, Pfizer, Olistic, Giuliani, and Almirall. Natasha Mesinkovska\u00a0reported personal fees from Lilly, Pfizer, Sun Pharma, and AbbVie during the conduct of the study. Arash Mostaghimi is an Editorial Board member of Dermatology and Therapy. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. He receives honoraria or advisory fees from hims and hers, AbbVie, Sun Pharma, Pfizer, Digital Diagnostics, Lilly, Equillium, ASLAN, Boehringer Ingelheim, Figure 1, Dermatheory, Olaplex, and Legacy Healthcare. Yutaka Shimomura has been an investigator for Eli Lilly and Company. Brett King has received fees from Abbvie, AltruBio Inc, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Aquestive, Aslan Pharmaceuticals, Bristol Meyers Squibb, CAGE Bio Inc, Concert Pharmaceuticals Inc, Eli Lilly and Company, Equillium, Galderma, GSK, Horizon Therapeutics, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Merck, Nektar, Novartis, Otsuka\/Visterra Inc, Pfizer Inc, Q32 Bio Inc, Regeneron, Sanofi Genzyme, Soterios, Sun Pharmaceutical, Takeda, TWi Biotechnology Inc, and Ventyx Biosciences Inc. He has served on speaker bureaus for Abbvie, Incyte, Eli Lilly, Pfizer, Regeneron and Sanofi Genzyme. He is a scientific advisor for BiologicsMD. Angelina Sontag, Fionn McSwiney, Najwa Somani, Hitendra Pandey, and Karen Denning are employees and shareholders of Eli Lilly and Company.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trials were conducted in accordance with ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines, and the research protocols were approved by each center\u2019s institutional review board or ethics committee. All patients provided written informed consent. The trials were reviewed and approved by ANMAT, Argentina (#DI-2019-1569-APN-ANMAT#MSYDS), Therapeutic Goods Administration, Australia (#CT-2019-CTN-00918-1), CONEP, Brazil (#3.499.010), NMPA\/CDE, China (#JXHL1900252), Israeli Ministry of Health, Israel (#6087-19-SMC), PMDA, Japan (#30-2603 and 31-0156), COFEPRIS (Secretar\u00eda de Salud), Mexico (#193300410A0031\/2019), Ministry of Food and Drug Safety, South Korea (#20190199878), Taiwan Food and Drug Administration, Taiwan (#1081490776) and Advarra, United States (#Pro00025373 and Pro00034650). The full list of ethics review boards is shown in Table S5.\u00a0Patients were not involved in the protocol development.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}